Haemonetics expands use of Arryx's optical trapping technology:
This article was originally published in Clinica
Braintree, Massachusetts-based Haemonetics has received expanded rights to use Arryx's optical trapping technology in a broader range of blood processing applications. The amended agreement will see Haemonetics make a one-off payment of $3m to Arryx for increased access to its technology. In addition, as agreed in the previous contract, Arryx will also receive milestone payments totalling a potential $12.4m for development and regulatory achievements. The two companies first entered a collaborative agreement in October last year, in which Haemonetics was granted an exclusive worldwide licence to Arryx's technology. The former also made a $5m equity investment in the Chicago, Illinois company.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.